Edward Hospital in Naperville is the first hospital in the Chicago area to use the LOTUS Edge Valve System to treat high-risk patients with severe aortic stenosis.
In September, Dr. Mark Goodwin, system medical director of the Cardiac Innovations & Structural Heart Center, assisted by Drs. Aman Ali, Stanley Clark, Peter Dejaegene (the Netherlands), Anand Ramanathan and William Stephan, implanted the LOTUS Edge in a 92-year-old male patient who had severe symptomatic aortic stenosis.
Aortic valve stenosis affects seven percent of all people over the age of 65. The only effective treatment is to replace the aortic valve. Left untreated, severe aortic stenosis can eventually lead to heart failure, severe infection and even sudden death.
LOTUS Edge is next-generation transcatheter aortic valve replacement (TAVR) technology that gives physicians the option to reposition and completely recapture the valve at full deployment in patients who have complex anatomical challenges.
As a non-surgical alternative for these patients, LOTUS Edge is delivered via a minimally invasive procedure to restore proper valve function.
LOTUS Edge is in a limited launch involving the top Structural Heart Centers in the United States and overseas.
At the time of the implant, Edward was one of only 15 hospitals in the country using the system, which was approved for use by the Food and Drug Administration (FDA) in April 2019.
LOTUS Edge is the only aortic valve approved by the FDA that is 100 percent repositionable, which enables physicians to precisely place the new valve into an optimal position in the heart, helping to improve outcomes for patients.
In addition to LOTUS Edge, procedures offered by the center include:
CardioMEMS HF System: For heart failure patients, a miniaturized, wireless monitoring sensor implanted during a minimally invasive procedure to directly measure pulmonary artery pressure, allowing patients to quickly and conveniently transmit data from their homes to their health care providers so they can be treated before patients become symptomatic.
Chronic total occlusion (CTO): Edward-Elmhurst treats CTO, or complete blockages, with a minimally invasive procedure that restores blood flow to the heart without open-heart surgery.
Left ventricular assist device (LVAD): For advanced heart failure, a surgically implanted system which takes over the pumping function of the heart's left ventricle.
MitraClip: A minimally invasive procedure for patients with degenerative mitral regurgitation who are too sick for open-heart surgery.
Transcatheter aortic valve replacement (TAVR): A minimally invasive surgical procedure for patients who suffer from severe aortic stenosis but are deemed too high-risk for traditional open-heart surgery.
WATCHMAN: A first-of-its-kind implant alternative to treat atrial fibrillation, which reduces the risk for stroke and enables patients to stop taking warfarin.
For more information about the Cardiac Innovations & Structural Heart Center at Edward, visit EEHealth.org/structural-heart.